In Vitro Diagnostics (IVD) Market Expected to Reach $91 Billion by 2027

1. In Vitro Diagnostics (IVD) Market Expected to Reach $91 Billion by 2027 Surge in incidence of infectious diseases, application of minimally invasive technologies, and prominence of personalized medicinal approach drive the global in vitro diagnostics market. According to a new report published by Allied Market Research, titled, “In Vitro Diagnostics Market by Product & Service,

2. Technique, Application, and End User: Opportunity Analysis and Industry Forecast, 2019–2026,” the global in vitro diagnostics market size was valued at $67 billion in 2019, and is expected to reach $91 billion by 2027, registering a CAGR of 4.8% from 2019 to 2027. Surge in incidence of infectious diseases, application of minimally invasive technologies, and prominence of personalized medicinal approach drive the global in vitro diagnostics market. However, stringent regulations and lack of standardized reimbursement policies restrain the market growth. On the other hand, convergence of innovative technologies and opportunities for outsourcing create new opportunities in the industry. Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/336 Based on technique, the immunodiagnostics segment held the highest market share in 2018, nearly one-third of the global IVD market, and this segment is expected to maintain its lead position during the forecast period. This is due to rise in prevalence of infectious diseases such as hepatitis C, HIV/AIDS, and others worldwide. However, the hematology segment is expected to register at the highest CAGR of 6.4% from 2018 to 2025, owing to high prevalence of blood related disorders including anemia, leukemia, polycythemia, hemophilia, and others along with launch of advanced high throughput screening hematology analyzers.

3. Based on application, the infectious diseases segment contributed to the largest share in 2018, contributing to more than one-fourth of the total share of the global IVD market. This is due to surge in demand of IVD screening for infectious disease. However, the cancer segment is estimated to grow at the highest CAGR of 7.0% from 2018 to 2025, owing to increase in incidence of various cancers across the globe, awareness related with early cancer diagnosis, and technological advancements. Based on region, North America held more than one-third of the global IVD market and is expected to maintain its leadership status throughout the forecast period. This is due to rise in infectious and chronic diseases incidence along with efforts taken toward spreading awareness related to early diagnosis of cancer. However, Asia-Pacific is estimated to maintain its highest CAGR of 5.9% during the forecast period, owing to rise in healthcare expenditure and technological advancements regarding screening of cancer. For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase- enquiry/336 Key market players discussed in the report include Abbott Laboratories, bioMérieux SA, Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter, Inc.), Bio-Rad Laboratories, Inc., Johnson & Johnson, F. Hoffmann-La Roche

4. Ltd., Sysmex Corporation, QIAGEN N.V., and Thermo Fisher Scientific, Inc.